Despite the scientific communities progress in translating microbiome R&D into promising therapeutic candidates, academic and pharmaceutical leaders continue to identify the causal role of the human microbiome in disease to create treatments with consistent clinical outcomes and predictable molecular mechanisms.
Part of the established Microbiome Movement, the 4th Microbiome Movement – Drug Development Europe returns as the industry-defining forum to help discover, develop and deliver the next generation of microbiome-based therapeutic and diagnostic candidates to market.
About the event
As the first microbiome-based therapeutic steps closer to market approval, the scientific community continue to demonstrate the functional role of the human microbiome as a novel source of therapeutic, biomarker and diagnostic development. Despite this progress, the vast potential to develop effective treatments that target the human microbiome is still limited by the complex challenges in developing them.
Part of the foremost conference series for microbiome researchers in industry, the 4th Microbiome Movement – Drug Development Europe 2020 returns to unite leading scientists from the biopharmaceutical and academic community to pursue the causal role of the microbiome in disease, and help create a new generation of microbiome-targeted therapeutics with predictable modes of action and consistent clinical outcomes.